Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 vs Chemotherapy in Previously Treated Advanced Urothelial Cancer
NCT06196736Phase 3Recruiting
- Sponsor
- Mabwell
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bulumtatug fuvedotin in urothelial carcinoma (UC), sponsored by Mabwell. Started Dec 2023; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06196736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196736.